Delcath Systems (DCTH) Q2 FY26 earnings call

The company delivered strong Q2 FY26 results, driven by significant HIPPSADO kit revenue growth and strategic expansion of its treatment center network. Management raised full-year revenue guidance, reflecting robust first-half performance and tempered seasonality expectations. While clinical trial enrollment faced initial challenges, the company is actively addressing these to advance its liver-directed platform into new indications.